Enhanced circulating soluble LR11 in patients with coronary organic stenosis

被引:33
|
作者
Takahashi, Mao [1 ]
Bujo, Hideaki [2 ]
Jiang, Meizi [2 ]
Noike, Hirofumi [1 ]
Saito, Yasushi [3 ]
Shirai, Kohji [4 ]
机构
[1] Toho Univ, Sakura Hosp, Med Ctr, Dept Cardiovasc Ctr, Chiba 2748510, Japan
[2] Chiba Univ, Grad Sch Med, Dept Genome Res & Clin Applicat, Chiba, Japan
[3] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chiba, Japan
[4] Toho Univ, Sakura Hosp, Med Ctr, Dept Internal Med, Sakura 2858741, Japan
关键词
LR11; Coronary stenosis; Hyperglycemia; Intimal smooth muscle cell; SMOOTH-MUSCLE-CELLS; INTIMAL-MEDIAL THICKNESS; RECEPTOR FAMILY-MEMBER; INSULIN-RESISTANCE; MIGRATION; EXPRESSION; ATHEROSCLEROSIS; OVEREXPRESSION; DISEASE;
D O I
10.1016/j.atherosclerosis.2009.12.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LR11, an LDL receptor family member, is expressed in intimal smooth muscle cells. It was found that the soluble form of LR11 (sLR11) is detected in serum, and the circulating sLR11 levels are positively correlated with intima-media thickness of carotid arteries in dyslipidemic subjects. To clarify the significance of serum sLR11, the circulating sLR11 levels in patients with organic coronary stenosis and the contributing risk factors for them were studied. The subjects, 150 patients with symptoms of coronary artery disease, underwent coronary angiographic examination, and were divided into sex-and age-matched two groups; one is organic coronary stenosis group (OCS) and the other is normal coronary group (NC). Serum sLR11 levels were significantly higher in OCS than in NC (4.9 +/- 2.7 U vs 3.6 +/- 1.8 U, p < 0.05). Multivariate regression analysis showed that circulating sLR11 is independent contributing factor for the OCS, as well as diabetes mellitus and dyslipidemia. Among various coronary risk factors for sLR11 level, HbA1c showed the highest correlation coefficient (p < 0.01). These results suggest that the circulating sLR11 might reflect coronary organic stenosis, and that hyperglycemic condition might be promoting factor for expression of LR11 in intimal smooth muscle cells. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:581 / 584
页数:4
相关论文
共 50 条
  • [31] Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease
    Watanabe, Kenichi
    Suzuki, Hiroshi
    Jiang, Meizi
    Haniu, Hisanori
    Numano, Fujito
    Hoshina, Satoshi
    Saitoh, Akihiko
    Uchiyama, Makoto
    Bujo, Hideaki
    ATHEROSCLEROSIS, 2016, 246 : 94 - 97
  • [32] Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans
    Andrew J. Whittle
    Meizi Jiang
    Vivian Peirce
    Joana Relat
    Sam Virtue
    Hiroyuki Ebinuma
    Isamu Fukamachi
    Takashi Yamaguchi
    Mao Takahashi
    Takeyoshi Murano
    Ichiro Tatsuno
    Masahiro Takeuchi
    Chiaki Nakaseko
    Wenlong Jin
    Zhehu Jin
    Mark Campbell
    Wolfgang J. Schneider
    Antonio Vidal-Puig
    Hideaki Bujo
    Nature Communications, 6
  • [33] PS4 - 3. Weight reduction decreases soluble LR11 in patients with type 2 diabetes
    Kirsten A.C. Berk
    Ranitha Vongpromek
    Hideaki Bujo
    Wolfgang Schneider
    Adrie J.M. Verhoeven
    Eric J.G. Sijbrands
    T. Mulder
    Nederlands Tijdschrift voor Diabetologie, 2013, 11 (4) : 144 - 144
  • [34] Soluble LR11 competes with amyloid β in binding to cerebrospinal fluid-high-density lipoprotein
    Yano, Kouji
    Hirayama, Satoshi
    Misawa, Naomi
    Furuta, Ayaka
    Ueno, Tsuyoshi
    Motoi, Yumiko
    Seino, Utako
    Ebinuma, Hiroyuki
    Ikeuchi, Takeshi
    Schneider, Wolfgang J.
    Bujo, Hideaki
    Miida, Takashi
    CLINICA CHIMICA ACTA, 2019, 489 : 29 - 34
  • [35] Soluble LR11 level is correlated with the severity of pulmonary hypertension due to left heart disease
    Joki, Yusuke
    Konishi, Hakuoh
    Takasu, Kiyoshi
    Shimada, Kazunori
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [36] Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma
    Ohwada, Chikako
    Yamazaki, Atsuko
    Kawaguchi, Takeharu
    Sugita, Yasumasa
    Takeuchi, Masahiro
    Shimizu, Naomi
    Sakaida, Emiko
    Takeda, Yusuke
    Tsukamoto, Shokichi
    Muto, Tomoya
    Jiang, Meizi
    Higashi, Morihiro
    Yokote, Koutaro
    Tamaru, Jun-ichi
    Bujo, Hideaki
    Nakaseko, Chiaki
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2982 - 2985
  • [37] Serum Soluble LR11 Can Predict High FLIPI-2 Score in Follicular Lymphoma.
    Kawaguchi, Takeharu
    Ohwada, Chikako
    Shimizu, Naomi
    Takeuchi, Masahiro
    Sakaida, Emiko
    Takeda, Yusuke
    Sakai, Shio
    Tsukamoto, Shokichi
    Yamazaki, Atsuko
    Higashi, Morihiro
    Tamaru, Jun-Ichi
    Yokote, Kotaro
    Bujo, Hideaki
    Nakaseko, Chiaki
    BLOOD, 2012, 120 (21)
  • [38] Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma
    Kawaguchi, Takeharu
    Ohwada, Chikako
    Takeuchi, Masahiro
    Shimizu, Naomi
    Sakaida, Emiko
    Takeda, Yusuke
    Sakai, Shio
    Tsukamoto, Shokichi
    Yamazaki, Atsuko
    Sugita, Yasumasa
    Higashi, Morihiro
    Fujikawa, Kazuhisa
    Matsue, Kosei
    Yokote, Koutaro
    Tamaru, Jun-Ichi
    Bujo, Hideaki
    Nakaseko, Chiaki
    LEUKEMIA & LYMPHOMA, 2014, 55 (10) : 2391 - 2394
  • [39] Impact of LR11 as residual risk on long term clinical outcomes in patients with coronary artery disease treated with statin after first percutaneous coronary intervention
    Takahashi, N.
    Ogita, M.
    Miyauchi, K.
    Wada, H.
    Naito, R.
    Konishi, H.
    Tsuboi, S.
    Dohi, T.
    Kasai, T.
    Okazaki, S.
    Isoda, K.
    Suwa, S.
    Bujo, H.
    Daida, H.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1042 - 1042
  • [40] Circulating soluble form of LR11, a regulator of smooth muscle cell migration, is a novel marker for intima-media thickness of carotid arteries in type 2 diabetes
    Jin, Wenlong
    Jiang, Meizi
    Han, Xinhua
    Han, Xuehua
    Murano, Takeyoshi
    Hiruta, Nobuyuki
    Ebinuma, Hiroyuki
    Piao, Lianshan
    Schneider, Wolfgang J.
    Bujo, Hideaki
    CLINICA CHIMICA ACTA, 2016, 457 : 137 - 141